Holen Sie sich die Stockscreener-App
176.80
0.71%
-1.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$178.07
Offen:
$177.46
24-Stunden-Volumen:
1.86M
Relative Volume:
1.05
Marktkapitalisierung:
$48.16B
Einnahmen:
$21.37B
Nettoeinkommen (Verlust:
$1.41B
KGV:
44.83
EPS:
3.9437
Netto-Cashflow:
$3.07B
1W Leistung:
-3.82%
1M Leistung:
-5.72%
6M Leistung:
+14.43%
1J Leistung:
-7.72%
1-Tages-Spanne:
$175.71
$178.13
1-Wochen-Bereich:
$175.71
$184.34
52-Wochen-Spanne:
$140.11
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, RMD, MDLN, ALC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
176.80 | 50.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
391.95 | 143.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
RMD
Resmed Inc
|
218.89 | 32.02B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.61 | 30.44B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
63.76 | 31.16B | 10.63B | 819.00M | 1.59B | 1.6577 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Fortgesetzt | Goldman | Neutral |
| 2026-02-10 | Fortgesetzt | Barclays | Overweight |
| 2026-02-03 | Fortgesetzt | Citigroup | Buy |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co (BDX) Insider Sale: EVP, Chief Revenue Off - GuruFocus
BDX.GE Bond Profile: Coupon and Redemption - TradingView
Form 4 Becton Dickinson and Co For: 29 September By Investing.com - Investing.com Nigeria
Becton Dickinson EVP Michael Feld sells $13,961 in BDX shares - Investing.com
An executive at Becton Dickinson (BDX) sells 76 shares at $183.70 each. - Stock Titan
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy – Company Announcement - Financial Times
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Could Becton Dickinson (NYSE:BDX) Reset Its Market Story? - Kalkine Media
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer - Yahoo Finance
Arthur Hu to Join BD as Chief Information and Digital Officer – Company Announcement - Financial Times
Becton, Dickinson and Company (BDX) Stock Analysis: Balancing Dividend Yield and Growth Potential - DirectorsTalk Interviews
A Lenovo executive is set to lead BD’s AI work - Stock Titan
Becton Dickinson (BDX), Why Is Fresh Attention Building Around It? - Simply Wall Street
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Why Has Becton Dickinson (BDX) Returned to the Spotlight? - Kalkine Media
Becton, Dickinson And Company Deploys BD Vmax 160 Pharmacy Automation Robot At Fairview Health Services - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: A Healthcare Giant with a 10% Potential Upside - DirectorsTalk Interviews
Fairview fills an average of 20,000 prescriptions a week. It is first in the U.S. to deploy a pharmacy robot. - Stock Titan
Did $40 Million Verdict Just Shift BD's (BDX) Investment Narrative? - simplywall.st
Becton Dickinson (BDX) Could Be 10% Undervalued As Dividend Lands - simplywall.st
Becton, Dickinson at Wells Fargo healthcare conference: focus sharpens - Investing.com
Becton, Dickinson at Wells Fargo healthcare conference: focus sharpens By Investing.com - Investing.com UK
Transcript : Becton, Dickinson and Company Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 through Sep-10-2026 - marketscreener.com
Becton Dickinson & Co's Dividend Analysis - Yahoo Finance Singapore
Is Becton Dickinson (BDX) Still A Bargain After A 24% Gain? - Simply Wall Street
Is Becton Dickinson & Co (BDX) a Bargain After 3.0% Drop? GF Val - GuruFocus
Jefferies Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $210 - Moomoo
Becton Dickinson & Co To Go Ex-Dividend On September 9th, 2026 With 1.05 USD Dividend Per Share - Moomoo
Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 5.91% Potential Upside in the Healthcare Giant - DirectorsTalk Interviews
How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks? - Yahoo Finance
BECTON DICKINSON & CO CFO Roque Vitor Retains 8,041 Shares Following 190-Share Forfeiture - Kalkine Media
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Becton Dickinson (NYSE: BDX) CFO reports 190-share tax withholding - Stock Titan
Quote and Chart - Becton Dickinson
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $200 - Moomoo
Becton, Dickinson and Company (BDX) Stock Analysis: Navigating Growth with a Solid Dividend Yield and Potential Upside - DirectorsTalk Interviews
BofA Adjusts Price Target on Becton Dickinson and Co. to $200 From $185 - Yahoo Finance
Becton Dickinson and Company (BDX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Becton Dickinson (BDX) Hits STANCE Trial Milestone, Is The Stock Fully Valued? - simplywall.st
Becton Dickinson (NYSE: BDX) CRO sale leaves him with 19,720 shares - Stock Titan
Becton, Dickinson and Company (BDX) Stock Analysis: Navigating Healthcare with a Strategic Edge - directorstalkinterviews.com
A continuous monitoring medtech vet charts the course to a less-invasive future - Medical Design & Outsourcing
16,962 Shares in Becton, Dickinson and Company $BDX Acquired by Wealthfront Advisers LLC - MarketBeat
Park West Asset Management LLC's Becton Dickinson & Co(BDX) Holding History - GuruFocus
Tocqueville Asset Management L.P. Raises Holdings in Becton, Dickinson and Company $BDX - MarketBeat
Flossbach Von Storch SE Sells 8,875 Shares of Becton, Dickinson and Company $BDX - MarketBeat
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):